ArticleNature2025
Reprogramming site-specific retrotransposon activity to new DNA sites.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing.Nature biotechnology · 2026Article
- Diversity and genome engineering applications of R2 non-LTR retrotransposons.RNA (New York, N.Y.) · 2026Review
- Programmable RNA-Guided DNA Recombination: Mechanisms, Engineering, and Applications.Biomedicines · 2026Review
- Article
- Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing.Nature biotechnology · 2026Article
- Synthetic Regulatory Genomics.Annual review of genomics and human genetics · 2026Review
- Prime editing-mediated microhomology enables efficient replacement of large DNA.Nucleic acids research · 2026Article
- Optimized R2 retroelement complexes for DNA insertion into plant genomes.Nature biotechnology · 2026Article
- Efficient site-specific gene addition using R2 retrotransposons in tobacco and rice.Nature biotechnology · 2026Article
- Fourth-generation gene editors: Integration-based genome engineering.Molecular therapy. Advances · 2026Review
- Integrating CRISPR genome editing with liver organoid and hiPSC-derived microfluidic platforms to model metabolic dysfunction-associated steatotic liver disease.Biochemistry and biophysics reports · 2026Review
- Programmable large-cargo integration: Overcoming size constraints for next-generation gene therapy.Synthetic and systems biotechnology · 2026Review
- Non-viral vectors as beacons of hope for reducing genotoxic risks of gene therapy.Nature biomedical engineering · 2026Article
- Precise, predictable genome integrations by deep-learning-assisted design of microhomology-based templates.Nature biotechnology · 2026Article
- CRISPy-web 3.0: A unified platform for multi-modal guide RNA design for CRISPR and TnpB genome editing applications.Synthetic and systems biotechnology · 2026Article
- Harnessing artificial intelligence to advance CRISPR-based genome editing technologies.Nature reviews. Genetics · 2026Review
- Synthetic rewriting technologies in mammalian cells.Nature communications · 2026Review
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.Journal for immunotherapy of cancer · 2026Review
- Rewriting the genome: harnessing R2 retrotransposons for precise DNA insertion.Frontiers in genome editing · 2026Review
- R2Tg retrotransposon mediated targeted integration of exogenous genes into the 28S rDNA locus in mammalian cell lines for PKU gene therapy.Frontiers in genome editing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Christopher W Fell *Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7343-3702
Lukas Villiger *McGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-2823-3271
Justin Lim *McGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4072-0371
Masahiro Hiraizumi *Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-4340-2937
Dario TagliaferriDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Matthew T N YarnallMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anderson LeeMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0005-3751-5408
Kaiyi JiangDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9569-5225
Alisan KayabolenDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5997-0894
Rohan N KrajeskiMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-6085-054X
Cian Schmitt-UlmsDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1310-9446
Harsh RamaniDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sarah M YousefMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nathaniel RobertsIntegrated DNA Technologies, Coralville, Iowa, USA.
Christopher A VakulskasIntegrated DNA Technologies, Coralville, Iowa, USA.ORCID 0000-0001-8510-4332
Hiroshi NishimasuDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2505-1416
Omar O AbudayyehDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. omar@abudayyeh.science.ORCID 0000-0002-7979-3220
Jonathan S GootenbergDepartment of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jgootenb@bidmc.harvard.edu.ORCID 0000-0003-2757-2175
Funding
Discovery and manipulation of transcription factors to restore long term stem cell repopulation in aged bone-marrowR01AG074932 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omar O Abudayyeh, Jonathan Samuel Gootenberg · 2022 to 2026
$3.3MProgrammable gene integration and cell engineering with CRISPR-directed integrasesR01EB031957 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2024
$2.4MSystematic discovery, characterization, and design of novel genome editing and delivery tools using a high-throughput metagenomic screening pipelineR21AI149694 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2020 to 2021
$414kRNA targeting tools with novel specific RNA-guided RNA-targeting CRISPR effectorsR56HG011857 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2021
$363kNHGRI NIH HHS R56 HG011857NIAID NIH HHS R21 AI149694NIA NIH HHS R01 AG074932NIBIB NIH HHS R01 EB031957
Abstract
Retroelements have a critical role in shaping eukaryotic genomes. For instance, site-specific non-long terminal repeat retrotransposons have spread widely through preferential integration into repetitive genomic sequences, such as microsatellite regions and ribosomal DNA genes
Indexed as
DNAGene EditingMutagenesis, InsertionalRetroelementsAnimalsCRISPR-Associated Protein 9CRISPR-Cas SystemsFinchesGenomeHumansMiceReverse TranscriptionCRISPR-Associated Protein 9DNARetroelements
Identifiers
PMID
40205048What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.